The invention provides an oral extended release formulation for the treatment of treatment-resistant depression, treatment-resistant anxiety, and phobia.

The present disclosure provides dosage form coating compositions and suspensions, coatings, coated dosage forms, and methods of making and using the same. The dosage form coating compositions can include a hydroxypropyl cellulose and a carboxymethylcellulose. The hydroxypropyl cellulose can be present in an amount by weight of at least 18.0% and at most 25.0%. The hydroxypropyl cellulose can be present in a ration of at least 1:1.4 and at most 1.4:1 relative to the carboxymethyl cellulose. The coated dosage forms can have an improved slip force, an improve swallowability as represented by an incline transit distance, or an improved gloss.

The present invention provides controlled release dosage formulations of compounds having the Formula:

##STR00001##

or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.

The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.

Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

The present invention relates to methods for treating patients with chronic cough with nalbuphine compositions as well as treating cough, breathlessness, or dyspnea associated with IPF with nalbuphine compositions, wherein the method provides a therapeutic effect in a patient.

The present invention relates to an oral pharmaceutical composition comprising a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof as an active ingredient, and a preparation method therefor.

The present invention relates to a pirfenidone formulation having improved safety and a method for producing same, wherein the pirfenidone formulation comprises pirfenidone as an active component, has two or more mutually different coatings selected from the group consisting of a coating containing a water-soluble polymer and a coating containing an enteric polymer, thereby specifically releasing pirfenidone in the small intestine, and has unique pharmacokinetic properties to reduce variability when pirfenidone is absorbed through the gastrointestinal tract, and reduce gastrointestinal side effects without affecting bioavailability of the active component, and therefore can remarkably improve low medication compliance.

The invention discloses use of a conjugate of polyethylene glycol and a local anesthetic in non-anesthetic analgesia. A local anesthetic is prepared into a prodrug or a sustained release preparation, wherein a high molecular polymer such as polyethylene glycol in the prodrug is covalently bonded with a local anesthetic, and auxiliary materials with a sustained release effect in the sustained release preparation are non-covalently bonded to the local anesthetic. After administration, there is no anesthesia and analgesic effect before the release of the free local anesthetic. After the free local anesthetic is released, an analgesic effect is achieved. And the prodrug or the sustained-release preparation of the local anesthetic of the present invention releases the drug slowly, and renders the drug concentration kept stable and long-lasting in the effective concentration range of non-narcotic analgesia, and the long-acting non-anesthetic analgesic effect can be achieved while significantly reducing the clinical adverse reactions of local anesthetics and reducing the number of administrations. The effectiveness of the drug is greatly enhanced and the clinical application range of local anesthetics is expanded.

The present disclosure provides pharmaceutical compositions of niclosamide that may be administered orally. These compositions may allow the achievement of a therapeutically effective dose of niclosamide while preventing crystallization in the stomach which reduces bioavailability. These compositions may be used to treat one or more diseases or disorders such as a viral infection or cancer.